Showing results (71-80 of 142) with videos related to

Sort By:
Pageof 15
Haematologica|November 17, 2018
EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysisAlessandro M Vannucchi, Peter A W Te Boekhorst, Claire N Harrison, et al.
Wiener Klinische Wochenschrift|July 26, 2018
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy managementMaria-Theresa Krauth, Sonja Burgstaller, Veronika Buxhofer-Ausch, et al.
American Journal of Hematology|February 17, 2015
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosisTiziano Barbui, Alessandro M Vannucchi, Alessandra Carobbio, et al.
Haematologica|March 28, 2008
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish familyKun Liu, Robert Kralovics, Zbigniew Rudzki, et al.
Wiener Klinische Wochenschrift|December 14, 2018
Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy managementMaria-Theresa Krauth, Sonja Burgstaller, Veronika Buxhofer-Ausch, et al.
Blood Cancer Journal|October 6, 2018
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivoEmmanuelle Verger, Juliette Soret-Dulphy, Nabih Maslah, et al.
Experimental Hematology & Oncology|September 18, 2015
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosisMary Frances McMullin, Claire N Harrison, Dietger Niederwieser, et al.
Frontiers in Cardiovascular Medicine|November 8, 2021
Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or CancerHenrike Arfsten, Anna Cho, Suriya Prausmüller, et al.
The New England Journal of Medicine|March 2, 2012
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosisClaire Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, et al.
Blood|July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportAyalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.
Pageof 15